Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr. Hu on the Increase in Incidence of Advanced Prostate Cancer

May 13th 2017

Jim C. Hu, MD, professor of Urology, Weill Cornell Medical College, discusses the increase in the incidence of advanced prostate cancer in the United States.

Dr. Morris on the Next Steps With Bone Biomarkers for Prostate Cancer

May 11th 2017

Michael J. Morris, MD, Memorial Sloan Kettering Cancer Center, discusses the next steps regarding bone biomarkers for patients with prostate cancer.

Dr. Dicker on DNA Sequencing for Prostate Cancer

May 10th 2017

Adam P. Dicker, MD, PhD, professor, chair, Department of Radiation Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, discusses DNA sequencing for patients with prostate cancer.

Dr. Slovin on the Challenges of Immunotherapy in Prostate Cancer

May 9th 2017

Susan F. Slovin, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the challenges of immunotherapy in prostate cancer.

Dr. Yu on the Significance of the PROTECT Study in Prostate Cancer

May 9th 2017

James B. Yu, MD, associate professor, therapeutic oncology, director, Prostate and Genitourinary Cancer Radiotherapy Program, Yale Cancer Center, discusses the significance of the PROTECT study results in prostate cancer.

Expert Discusses Unleashing Promise of Genetic Testing in Prostate Cancer

May 8th 2017

Christopher J. Kane, MD, discusses the challenges and impact of genetic testing on patients with prostate cancer.

Dr. Febbo on the Impact of Oncotype DX Genetic Prostate Score

May 6th 2017

Phil Febbo, MD, chief medical officer, Genomic Health, discusses the impact the Oncotype DX Genetic Prostate Score (GPS) has on patients with clinically low-risk prostate cancer.

Novel Blood Test May Identify New Biomarker in Prostate Cancer

May 5th 2017

Researchers may be able to predict which patients with CRPC are most likely to have poorer outcomes while undergoing targeted therapy, according to the results of the PREMIERE trial.

Dr. Kirsh on Advancements in Diagnosing Prostate Cancer

May 5th 2017

Gary Kirsh, MD, president of The Urology Group and the Large Urology Group Practice Association (LUGPA), discusses advancements in diagnosing patients with prostate cancer.

Novel Imaging Agent May Improve Prostate Cancer Detection

May 2nd 2017

An investigational radiotracer that targets prostate-specific membrane antigen is being tested in patients with high-risk, recurrent, or metastatic prostate cancer to determine whether the novel agent can improve upon the sensitivity and specificity of conventional imaging.

Dr. Yu on Moderate Hypofractionation in Prostate Cancer

May 2nd 2017

James B. Yu, MD, associate professor, therapeutic oncology, director, Prostate and Genitourinary Cancer Radiotherapy Program, Yale Cancer Center, discusses moderate hypofractionation replacing the current standard of care for patients with prostate cancer.

Abiraterone Shows Promise in Prostate Cancer After Hormone Induction Failure

April 27th 2017

Thomas Flaig, MD, discusses the study of abiraterone acetate in metastatic prostate cancer after hormone induction failure and its impact on future research in this setting.

ASCO Issues Guidance on Second-Line Treatment of CRPC

April 25th 2017

Informed by new clinical evidence, ASCO has issued updated guidance on the use of second-line hormonal therapy for chemotherapy-naïve patients with castration-resistant prostate cancer.

Dr. Higano Discusses PARP Inhibitors in Prostate Cancer

April 25th 2017

Celestia Higano, MD, professor of medicine and urology at the University of Washington, and a member of the Clinical Research Division at Fred Hutchinson Cancer Research Center, discusses PARP inhibitors in prostate cancer.

Significance of Analyzing Gene Mutations in Prostate Cancer

April 25th 2017

Joshua Armenia, PhD, Memorial Sloan Kettering Cancer Center, discusses the significance of analyzing mutated genes in prostate cancer.

Expert Highlights Rapidly Evolving Biomarker Development in Prostate Cancer

April 24th 2017

Leonard Gomella, MD, discusses the future of biomarkers in prostate cancer.

Dr. Chapin on Impact of Active Surveillance in Field of Prostate Cancer

April 22nd 2017

Brian F. Chapin, MD, assistant professor, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses impact of active surveillance in the field of prostate cancer.

Dr. Slovin on the Future of Immunotherapy in Prostate Cancer

April 21st 2017

Susan F. Slovin, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the future of immunotherapy for patients with prostate cancer.

Dr. Kane on Genetic Testing for Prostate Cancer

April 20th 2017

Christopher J. Kane, MD, professor of Surgery, chair, Department of Urology, UC San Diego Health, discusses the impact of genetic testing on patients with prostate cancer.

Dr. Crawford on Ongoing Trials of Genetic Testing for Prostate Cancer

April 20th 2017

E. David Crawford, MD, professor of Radiation Oncology, University of Colorado School of Medicine, discusses ongoing trials regarding genetic testing for patients with prostate cancer.